^(125)I放射性粒子组织间植入治疗腮腺癌专家共识(2023年版)  

Expert consensus on iodine-125 interstitial brachytherapy for parotid gland cancer(2023 edition)

作　　者：中国抗癌协会口腔颌面肿瘤整合医学专业委员会 中国抗癌协会肿瘤微创治疗专业委员会 张杰[2] 刘树铭[2] 李振宇 张建国[2] 黄明伟[2] 郑磊[2] Society of Integrative Medicine on Oral Maxillofacial Oncology of China Anti-Cancer Association;Society of Minimally Invasive Therapy of China Anti-Cancer Association;Zhang Jie(不详;Department of Oral and Maxillofacial Surgery,Peking University School of Stomatology,Beijing 100081,China)

机构地区：[1]不详 [2]北京大学口腔医院口腔颌面外科,北京100081

出　　处：《中华放射医学与防护杂志》2023年第11期851-857,共7页Chinese Journal of Radiological Medicine and Protection

摘　　要：^(125)I放射性粒子组织间植入治疗是腮腺癌主要治疗方法之一,具有局部剂量高和周围组织损伤小的特点。放射性粒子治疗效果与剂量、精度密切相关。然而,125I放射性粒子在腮腺癌中的应用尚无明确规范,各治疗中心对于放射性粒子治疗的标准不尽相同。为进一步规范腮腺癌近距离放射治疗流程,经国内多位专家反复讨论后达成一致意见,制定本共识。本共识对125I放射性粒子组织间植入治疗腮腺癌的适应证与禁忌证、治疗参数、操作流程、技术规范、放射防护、不良反应、随访等给出了规范化建议,可供临床实践参考。Iodine-125(^(125)I)interstitial brachytherapy,a primary method for treating parotid gland cancer,allows for a high dose to the target area while protecting surrounding normal tissues.The efficacy of radioactive 125I seeds is closely related to the dose and accuracy.However,there is a lack of specifications for the application of radioactive ^(125)I seeds in the treatment of parotid gland cancer presently,with relevant criteria differing greatly between medical centers.To further standardize the process of ^(125)I interstitial brachytherapy for parotid gland cancer,this expert consensus was achieved through repeated discussions and modifications of many Chinese experts in the field of brachytherapy.This consensus,consisting of the normative recommendations on the indications,contraindications,treatment parameters,operation process,technical specifications,radiation protection,adverse reactions,and follow-up of the brachytherapy,can be used as a reference for clinical practice.

关 键 词：^(125)I放射性粒子 腮腺癌 专家共识 

分 类 号：R730.55[医药卫生—肿瘤] R739.8[医药卫生—临床医学]